How are ELAN strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ELAN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 47.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$220.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ELAN strangle?

The breakeven for the ELAN strangle priced on this page is roughly $16.80 and $23.20 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ELAN market-implied 1-standard-deviation expected move is approximately 13.73%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ELAN implied volatility affect this strangle?

ELAN ATM IV is at 47.90% with IV rank near 35.84%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

ELAN Strangle Strategy

ELAN (Elanco Animal Health Incorporated), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NYSE.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

ELAN (Elanco Animal Health Incorporated) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $10.89B, a beta of 1.69 versus the broader market, a 52-week range of 12.4-27.72, average daily share volume of 5.5M, a public-listing history dating back to 2018, approximately 9K full-time employees. These structural characteristics shape how ELAN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.69 indicates ELAN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on ELAN?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ELAN snapshot

As of May 15, 2026, spot at $19.97, ATM IV 47.90%, IV rank 35.84%, expected move 13.73%. The strangle on ELAN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this strangle structure on ELAN specifically: ELAN IV at 47.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 13.73% (roughly $2.74 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ELAN expiries trade a higher absolute premium for lower per-day decay. Position sizing on ELAN should anchor to the underlying notional of $19.97 per share and to the trader's directional view on ELAN stock.

ELAN strangle setup

The ELAN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ELAN near $19.97, the first option leg uses a $21.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ELAN chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ELAN shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$21.00	$1.18
Buy 1	Put	$19.00	$1.03

ELAN strangle risk and reward

Net Premium / Debit: -$220.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$220.00
Breakeven(s): $16.80, $23.20
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ELAN strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ELAN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$1,679.00
$4.42	-77.8%	+$1,237.56
$8.84	-55.7%	+$796.13
$13.25	-33.6%	+$354.69
$17.67	-11.5%	-$86.75
$22.08	+10.6%	-$111.81
$26.50	+32.7%	+$329.62
$30.91	+54.8%	+$771.06
$35.32	+76.9%	+$1,212.50
$39.74	+99.0%	+$1,653.93

When traders use strangle on ELAN

Strangles on ELAN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ELAN chain.

ELAN thesis for this strangle

The market-implied 1-standard-deviation range for ELAN extends from approximately $17.23 on the downside to $22.71 on the upside. A ELAN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ELAN IV rank near 35.84% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ELAN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ELAN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ELAN-specific events.

ELAN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ELAN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ELAN alongside the broader basket even when ELAN-specific fundamentals are unchanged. Always rebuild the position from current ELAN chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ELAN?: A strangle on ELAN is the strangle strategy applied to ELAN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ELAN stock trading near $19.97, the strikes shown on this page are snapped to the nearest listed ELAN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ELAN strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ELAN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 47.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$220.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ELAN strangle?: The breakeven for the ELAN strangle priced on this page is roughly $16.80 and $23.20 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ELAN market-implied 1-standard-deviation expected move is approximately 13.73%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ELAN?: Strangles on ELAN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ELAN chain.
How does current ELAN implied volatility affect this strangle?: ELAN ATM IV is at 47.90% with IV rank near 35.84%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.